Table 3. Multiple regression analysis of TRM at 6 months following nonmyeloablative HCT.

Factor	Relative Risk of TRM (95% CI)	P-value
F-ara-A AUC(0-∞)		.02
≤ 6.5 ug hr/mL*	1.00
> 6.5 ug hr/mL	4.56 (1.22-17.14)
Age (yrs)		.89
< 55*	1.00
≥ 55	0.92 (0.26-3.20)
ATG in conditioning regimen		.09
Yes*	1.00
No	0.36 (0.11-1.19)
Recipient CMV status		.93
Negative*	1.00
Positive	0.94 (0.27-3.34)
Donor Source		.97
Matched-related*	1.00
Unrelated	1.03 (0.31-3.40)
Comorbidity Score		.18
0*	1.00
1-2	0.22 (0.04-1.25)
≥3	0.60 (0.12-2.98)
Creatinine clearance		.41
≥ 70 ml/min*	1.00
< 70 ml/min	1.63 (0.52-5.13)
aGVHD grades III-IV		.15
No*	1.00
Yes	2.91 (0.67-12.60)

^*reference group